Cetrelimab,TAR-200
janssen
['tar200', 'gemcitabine', 'mibc', 'transform,(-transformi),(-transforme),(-transforma),(-transforms),(-transform1),(-transform 1),(-transform-1),(-transform2),(-transform 2),(-transform-2)', 'sunrise 1', 'sunrise']
a phase 1 study of a novel intravesical drug delivery system (tar200) #aacr23 slow release of gemcitabine in t2n0m0 showed pcr= 30%, pfs= 10 mnths. these promising data underpin the v. important sunrise 1-4 clinical program, which looks to transform mibc. 
Interested in Urology Cancers, biomarkers and drug development.